Evaluation of Three Amikacin Administration Regimens byPharmacokinetic Modelling in Patients with Cystic Fibrosis
Authors:
M. Halačová; R. Průša; K. Kotaška; V. Vávrová 1
Authors‘ workplace:
Ústav klinické biochemie a patobiochemie 2. LF UK a FNM, Praha 1II. dětská klinika 2. LF UK a FNM, Praha
Published in:
Čas. Lék. čes. 2004; : 187-190
Category:
Overview
Background.
Once-daily administration of aminoglykosides is routinely used, but comparative efficacy data forpatients with cystic fibrosis are not available.Methods and Results. The aim of the this study was to compare the predicted pharmacodynamic (PD) activity ofamikacin at 28 mg/kg/den administered every 24 hod.(q24 h), q12 h, and q8 h. Pharmacokinetic (PK) data werederived from analysis of the amikacin serumconcentration from42 CF children patients. Individual pharmacokineticsvalues were used to construct serum concentration-versus time curves and to determine various indices (c peak/MICratio and time during the concentration was less than theMIC – T
Key words:
cystic fibrosis, amikacin, pharmacokinetic parameters, MIC.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Molecular Diagnostics of Malignant B Cell Lymphomas: Detection ofClonality and a Brief Review with our Own Results
- Intelligence Loss in Phatic Disorders
- Budd-Chiari Syndrome in Patient with Primary ThrombocythaemiaTreated with Interferon Alpha Medically Managed by Transjugular Porto-systemic Shunt
- Results of Clinical Study of Patients Suffering from Hodgkin’s Lymphomaafter 25 Years